ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a ...

Q3 reiterated FY 2026 gross margin range “62% to 63%” (CFO Sandercock), consistent with Q2’s updated FY 2026 gross margin range.

ResMed Inc (RMD) reports an 11% revenue increase and strategic acquisition plans, while navigating supply chain challenges and competitive pressures.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales ...

Choosing the right CPAP mask can make or break your sleep therapy success. From cushion materials to strap adjustments, small details change comfort and adherence. New designs and clever hacks are ...

Take advantage of our free shipping offer for this item! We offer free shipping on all parcel shipments within the contiguous United States. For further information, please refer to our Shipping ...

Resmed Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for sma ...